Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults

AIDS

Volumn 12, Issue 16, 1998, Pages

  Saag, Michael S ^a,i   Sonnerborg, Anders ^b   Torres, Ramon A ^c   Lancaster, Danny ^d   Gazzard, Brian G ^e   Schooley, Robert T ^f   Romero, Carmen ^g   Kelleher, Dennis ^h   Spreen, William ^h   LaFon, Stephen ^h  

^a University of Alabama at Birmingham   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ST VINCENT S HOSPITAL   (United States)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f UNIVERSITY OF COLORADO   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

^h GLAXOSMITHKLINE   (United States)

ⁱ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Abacavir; Combination drug therapy; HIV infection; Reverse transcriptase inhibitors; Zidovudine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ARTICLE; ASTHENIA; BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HEART PALPITATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; INSOMNIA; LEUKOPENIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOTOPHOBIA; PRIORITY JOURNAL; RASH; SYNCOPE; VERTIGO; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DIDEOXYNUCLEOSIDES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV-1; HUMANS; MALE; RNA, VIRAL; TIME FACTORS; VIRAL LOAD; ZIDOVUDINE;

EID: 7844252581     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199816000-00002     Document Type: Article

References (15)

1. Daluge SM, Good SS, Faletto MB, et al.: 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 1997, 41: 1082-1093.
2. Faletto MB, Miller WH, Garvey EP, St Clair MH, Daluge SM, Good SS: Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother 1997, 41:1099-1107.
3. Tisdale M, Alnadaf T, Cousens D: Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997, 41:1094-1098.
4. Ravitch JR, Sadler BM, McDowell JP, Walsh JS: In vivo and in vitro studies of the potential for drug interactions involving the anti-retroviral 1592 in humans. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 634].
5. Kumar PN, Sweet DE, McDowell JA, et al.: Safety and pharmacokinetics of abacavir (1592U89), a nucleoside analog, following oral administration of escalating single doses. Submitted to Antimicrob Agents Chemother 1998.
6. Brun-Vezinet F, Boucher C, Loveday C. et al.: HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. Lancet 1997, 350:983-990.
7. Eron JJ: The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS 1996, 10 (suppl 5):S11-S19.
8. Katlama C, Ingrand D, Loveday C, et al.: Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviralnaive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 1996, 276:118-125.
9. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995, 333:1662-1669.
10. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996, 335:1081-1090.
11. Delta Coordinating Committee: Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996, 348:283-291.
12. Kitchen VS, Skinner C, Ariyoshi K, et al.: Safety and activity of saquinavir in HIV infection. Lancet 1995, 345:952-955.
13. Massari F, Conant M, Mellors J, et al.: A phase II open-label, randomized study of the triple combination of indinavir, zidovudine (ZDV) and didanosine (DDI) versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients. Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, January-February 1996 [abstract 200].
14. Chodakewitz JA, Leavitt R, Massari F, et al.: Crixivan: summary of 24-week experience with Crixivan at 2.4g/d in phase II trials. XI International Conference on AIDS. Vancouver, July 1996 [abstract MoB1144].
15. Pym AS, Churchill DR, Galpin S, et al.: Sustained benefit after four years of saquinavir monotherapy. XI International Conference on AIDS. Vancouver, July 1996 [abstract TuB2123].